Dr Joerg Reinhardt appointed new ceo of Bayer HealthCare

Dr Marijn Dekkers to head the subgroup temporarily from 1 May

Dr Jörg Reinhardt has been appointed chairman of the board of management of Bayer HealthCare AG and chairman of the Bayer HealthCare executive committee with effect from 15 August, 2010. He was latterly chief operating officer of Novartis.

Current HealthCare ceo Arthur J. Higgins will leave the company as planned on 30 April at his own request. Dr Marijn Dekkers, member of the Bayer board of management and its designated chairman, will additionally take over as head of Bayer HealthCare on a temporary basis from 1 May until Dr Reinhardt’s appointment takes effect.

‘Dr Reinhardt is an acknowledged expert with many years of experience in the healthcare industry,’ said Werner Wenning, chairman of the board of management of Bayer AG. ‘We are convinced of his ability to provide a decisive impetus to our global HealthCare business and further expand our strong competitive positions.’

You may also like

Distribution

PanTera signs agreement with Bayer for the supply of actinium-225

The company will provide 225Ac for clinical trial needs
Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Packaging

Bayer joins the Blister Pack Collective to reduce single-use plastics in tablet packs

PA Consulting (PA), the company bringing ingenuity to life, and PulPac, the Swedish R&D and IP company behind Dry Molded Fiber, are pleased to announce the Consumer Health division of Bayer has joined the Blister Pack Collective
Ingredients

Therapeutic: asundexian for atrial fibrillation

In atrial fibrillation, the atria of the heart contract irregularly; as a result, they do not empty completely and prevent the correct flow of blood
Manufacturing

Topping-out ceremony for the world's first AI-enhanced drug production facility

Glatt is system integrator for a Bayer investment of around 275 million euros
Manufacturing

Bayer to implement Infor EAM at Bitterfield site

Implementation will be handled by Infor partner Rodias
Finance

Bayer strengthens cell and gene therapies with BlueRock acquisition

BlueRock Therapeutics is a privately-held biotech company headquartered in the US
Subscribe now